CClinicalTrials.gg
RecruitingNCT07025733Updated May 1, 2026

Semiconductor Embedded Socks for Ankle Sprains

An interventional study of Semiconductor Embedded Sock and Control Compression Sock in Ankle Sprain, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by University of Colorado, Denver · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The goal of this clinical trial is to determine if semiconductor fabric embedded in socks can improve healing after non operative ankle sprains. The main questions it aims to answer are:

  1. How does semiconductor embedded sock effect outcomes in patients undergoing rehabilitation from ankle injury?
  2. How does semiconductor embedded socks effect injury symptoms and function throughout the course of treatment?

Researchers will compare semiconductor embedded socks with typical compression socks to determine differences in healing.

Participants will be given the socks and be asked to wear them throughout the healing process and record symptoms and functional measures.

Read the detailed description

STUDY SUMMARY Injuries to the foot and ankle are highly prevalent, with great susceptibility to various injury types due to high usage and complex structural makeup. Ankle injuries are responsible for over 1 million Emergency Room visits each year, and ankle sprains are seen at an incidence of up to 19.0 - 26.6 per 1000 person-years. Approximately 2 million ankle sprains occur annually in the United States alone, and the incidence of re-injury is high, between 12 - 47% of reported ankle sprains are recurrent following initial injury. Ankle sprains are the most commonly presenting sports-related injury each year. Lateral ankle sprains are the most commonly reported type of ankle sprains compared to syndesmotic and medial sprains, and females are at greater risk of sustaining an ankle sprain compared with male counterparts.

Symptoms include pain, swelling, instability and tenderness. Ankle sprains are generally considered treatable and return to activity and sport are typically expected to be successful with proper rehabilitation adherence and measures taken to reduce risk of complication.

The proposed study seeks to evaluate the effectiveness of a non-compressive, therapeutic socks throughout a 12-week course of rehabilitation for non-surgically treated ankle sprain or fracture injury. Outcome measures will be collected at standard intervals up to 1 year to evaluate effectiveness of treatment.

BACKGROUND Treatment approaches for ankle injuries are dictated by the injury type and severity, and include early immobilization, bracing and splinting, return to mobilization as tolerated, rehabilitation strengthening exercises, stabilizing shoes or devices, and pain medication.

Evidence from Lamb, et. al supports a period of up to 14 days of immobilization in a below-knee cast or Aircast instead of a tubular compression bandage and demonstrates improved quality of ankle function after 3 months.

Unlike compression products, the therapeutic socks which will be used in this study are made with semiconductor embedded fabric. The socks increase blood circulation through activation of the embedded elements with heat of the body, and releases mid and far infrared waves as well as negative ions. Both infrared waves and negative ions are biologically active and mediate inflammatory and pain pathways in the body. The technology has also been shown to:

  • Increase blood flow and velocity
  • Reduce osteoarthritis pain
  • Reduce effusion post total knee arthroplasty
  • Improve chondrogenic differentiation in vitro
  • Improve muscle recovery
  • Increase blood speed by up to 22% at rest
  • Improve functional outcomes

The benefits of the Infrared Wave and Negative Ion therapy include:

  • Inhibition of Cox-2 and Prostaglandins in the lipopolysaccharide (LPS)-moderated pain pathway
  • Up-regulation of heat shock protein
  • Mediated Nitric oxide production
  • Increased activity of voltage-gated ion channels
  • Increased activity of mechanosensitive ion channels
  • Polarization of cell surface membranes
  • Protecting muscle damage
  • Scavenging of Reactive Oxygen Species (ROS)
  • Improved thermoregulation

The semiconductor embedded fabric emits mid-level and far infrared waves and negative ions. Delivery of infrared waves and negative ions to the tissue increases circulation of both blood and lymph, facilitates the anti-inflammatory nitric oxide (NO) cascade by accelerating the binding of calcium (Ca2+) to calmodulin (CaM). NO provides several healing factors to the body, increasing blood and lymphatic flow6. Additionally, NO down-regulates interleukin-1 beta (IL1β) and inducible nitric oxide synthase (iNOS) in certain cell types, which leads to reduced cyclooxygenase-2 (COX-2) and prostaglandins - molecules responsible for causing inflammation and pain. Unlike other systemic COX-2 inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), targeted infrared and negative ion therapy stimulate localized reaction pathways, thereby reducing pain and inflammation.

This study seeks to identify subjective and objective outcomes for management of ankle sprain, non-operative distal fracture or avulsion fracture injuries through application of semiconductor embedded socks to the affected area.

OBJECTIVES

  1. Determine the effect of the semiconductor embedded sock on outcomes in patients undergoing rehabilitation from ankle injury.
  2. Evaluate the change in ankle injury symptoms and function in patients throughout the course of treatment with the semiconductor embedded sock.
02

Conditions studied

  • Ankle Sprain

Keywords

  • ankle sprain
  • ligamentous sprain
  • avulsion fracture
  • distal fibula fracture
03

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Ankle sprain, avulsion fracture, distal fibular fracture
  • Pain for at least 1 day
  • Patients 18-69 years old

Exclusion criteria

Exclusion Criteria:

  • Patients with neurological conditions
  • Patients with prior surgical treatment of lower limb injury
  • Patients with chronic pain conditions
  • Patient with auto-immune or auto-inflammatory disease
  • Patients with tobacco use in last 90 days
  • Patients with history of metabolic disorders
  • Patients with open wound at area of application
  • Patients with acute or systemic infection
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Semiconductor Embedded Sock

    Device: Semiconductor Embedded Sock

  • Placebo comparator
    Control Compression Sock

    Device: Control Compression Sock

Interventions

  • DeviceSemiconductor Embedded Sock

    Semiconductor Embedded sock will be given to this intervention arm

  • DeviceControl Compression Sock

    Control sock that is just compression sock

05

What researchers measure

Primary outcomes

  1. FAOS Score

    Improved patient function compared to placebo group as determined by pre-treatment and post-treatment Patient Specific Foot Function Index Foot and Ankle Outcome Score (FAOS) compared to placebo group. Range of Scores: \[0-100\], higher scores indicates a better outcome.

    Time frame: 6 months

06

Study locations

1 of 1 sites recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07025733
Lead sponsor
University of Colorado, Denver
Collaborators
University of Colorado Health, INCREDIWEAR HOLDINGS, INC.
Responsible party
Sponsor
First posted
Jun 17, 2025
Start date
Apr 10, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
May 1, 2026

Study contacts

Study Coordinator
Contact
fahim.choudhury@cuanschutz.edu
3037243185
Nicholas Alfonso, MD
principal investigator · University of Colorado Department of Orthopedics

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion